# Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

> **NCT02900183** · PHASE2 · WITHDRAWN · sponsor: **Arrowhead Pharmaceuticals**

## Conditions studied

- Alpha-1 Antitrypsin Deficiency

## Interventions

- **DRUG:** ARC-AAT Injection

## Key facts

- **NCT ID:** NCT02900183
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision to not initiate trial
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900183, "Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02900183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*